Current status of therapy for chronic myeloid leukemia: a review of drug development

被引:10
作者
Padmanabban, Swami [2 ]
Ravella, Saritha [2 ]
Curiel, Tyler [2 ]
Giles, Francis [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, CTRC Inst Drug Dev, San Antonio, TX 78229 USA
[2] Canc Therapy & Res Ctr S Texas, Inst Drug Dev, Dept Hematol Oncol, San Antonio, TX 78229 USA
关键词
CML; cytogenic remission; dasatinib; imatinib; IRIS; molecular remission;
D O I
10.2217/14796694.4.3.359
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncommon. Even though the treatment failure rate is low, the emergence of drug resistance and the lack of eradication of the hematopoietic stem cell clone has prompted a wave of drugs to address one or both these problems. Several clinical trials (Phase I and II) of dasatinib or nilotinib in the treatment of imatinib-resistant or -intolerant Ph chromosome-positive leukemia have already reported a remarkable rate of hematologic response greater than 90% for chronic-phase patients. These drugs minimize the risk of acquired drug resistance that is particularly seen within the first 24-36 months of therapy, and can prevent early failure in these patients, Furthermore, rational, noncross-resistant combinations that include a T3151 inhibitor and drugs that can eradicate the hematopoietic stem cell clone may extend the coverage to virtually all patients with bcr-abl. Here we review the 6-year impact of the 'magic pill', Gleevec (R), (Glivec (R)), including the emerging problems with its treatment, the efficacy data of dasatinib and nilotinib and the very promising data of the newer generation of drugs for CML.
引用
收藏
页码:359 / 377
页数:19
相关论文
共 76 条
  • [1] [Anonymous], BLOOD
  • [2] Baccarani M, 2006, BLOOD, V108, p53a
  • [3] Altered bone and mineral metabolism in patients receiving imatinib mesylate
    Berman, E
    Nicolaides, M
    Maki, RG
    Fleisher, M
    Chanel, S
    Scheu, K
    Wilson, BA
    Heller, G
    Sauter, NP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) : 2006 - 2013
  • [4] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
    Branford, S.
    Cross, N. C. P.
    Hochhaus, A.
    Radich, J.
    Saglio, G.
    Kaeda, J.
    Goldman, J.
    Hughes, T.
    [J]. LEUKEMIA, 2006, 20 (11) : 1925 - 1930
  • [5] BRANFORD S, 2006, BLOOD, V108
  • [6] Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
    Brave, Michael
    Goodman, Vicki
    Kaminskas, Edvardas
    Farrell, Ann
    Timmer, William
    Pope, Sarah
    Harapanhalli, Ravi
    Saber, Haleh
    Morse, David
    Bullock, Julie
    Men, Angela
    Noory, Carol
    Ramchandani, Roshni
    Kenna, Leslie
    Booth, Brian
    Gobburu, Joga
    Jiang, Xiaoping
    Sridhara, Rajeshwari
    Justice, Robert
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (02) : 352 - 359
  • [7] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
    Bumm, T
    Müller, C
    Al-Ali, HK
    Krohn, K
    Shepherd, P
    Schmidt, E
    Leiblein, S
    Franke, C
    Hennig, E
    Friedrich, T
    Krahl, R
    Niederwieser, D
    Deininger, MWN
    [J]. BLOOD, 2003, 101 (05) : 1941 - 1949
  • [8] Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
    Burgess, MR
    Skaggs, BJ
    Shah, NP
    Lee, FY
    Sawyers, CL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) : 3395 - 3400
  • [9] COPLAND IM, 2006, BLOOD, V108
  • [10] To the editor: Discontinuation of imatinib therapy after achieving a molecular response
    Cortes, J
    O'Brien, S
    Kantarjian, H
    [J]. BLOOD, 2004, 104 (07) : 2204 - 2205